NIH expands program to crack medical mysteries

Click to view the privacy policy. Required fields are indicated by an asterisk (*) Harvard Medical School in Boston, which received a $9 million award in January to act as “coordinating center,” will facilitate collaboration between researchers and will make patient data widely available through public repositories such as NIH’s database of Genotypes and Phenotypes, explained Anastasia Wise, director of NHGRI’s Division of Genomic Medicine, at a press conference today.Since the program launched in May 2008, it has received applications from about 3200 patients, 750 of which were selected for study. “There has never been a shortage of referrals to the program,” UDP Director William Gahl said today. (Indeed, in 2011, the program temporarily stopped accepting applications to catch up on the flood of inquiries.) The program’s track record for medical sleuthing depends on how you define a diagnosis, Gahl said. Between 25% and 50% of cases are considered “resolved” based on a clinical, molecular, or biochemical diagnosis, while about a quarter are closed without an answer. “You can see that this is a difficult work, in which we sometimes fail,” he added.The program now admits about 150 patients per year at the NIH Clinical Center, but plans to accommodate 50 per year at each of the seven sites by the summer of 2017. Email Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Sign up for our daily newsletter Get more great content like this delivered right to you! Country An effort at the U.S. National Institutes of Health (NIH) to diagnose mysterious diseases is undergoing a major expansion. Representatives of the Undiagnosed Diseases Program (UDP), administered by NIH’s National Human Genome Research Institute (NHGRI), announced today that six medical centers will join the program, forming a network of clinical sites to investigate intractable cases from patients around the country. The program aims to offer patients a long-awaited diagnosis—and sometimes treatment—while building up data for scientists studying the genetic basis of rare diseases.The new sites—Baylor College of Medicine; the Harvard teaching hospitals (Boston Children’s, Brigham and Women’s, and Massachusetts General); Duke University; Stanford University; the University of California, Los Angeles; and Vanderbilt University Medical Center—will each receive a 4-year grant of roughly $7.2 million to participate. Like the NIH Clinical Center in Bethesda, Maryland, that served as a pilot site, the centers will host patients for about a week at a time, performing extensive clinical tests and genetic sequencing in search of an explanation for their symptoms.

Leave a Reply

Your email address will not be published. Required fields are marked *